2020.07.09 02:20
No. | Subject | Date | Author | Last Update | Views |
---|---|---|---|---|---|
Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18193 |
Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32348 |
Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5924 |
Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43840 |
623 | ♥ 스텐트로 PCI를 우선 시행해도 심근경색과 사망은 감소하지 않음 | 2010.02.08 | 이종구*57 | 2010.02.08 | 7342 |
622 | 심장돌연사 | 2010.02.10 | 이종구*57 | 2010.02.10 | 6932 |
621 | ♥ 약물방출 스텐트는 금속에 비해 혈전증과 심근경색증을 증가 가능 | 2010.02.15 | 이종구*57 | 2010.02.15 | 7928 |
620 | ♥ 부정맥 바로알자 | 2010.02.17 | 이종구*57 | 2010.02.17 | 7889 |
619 | ♥ 약물방출 스텐트(DES)환자에서 clopidogrel을 중단하면 심근경색과 사망률이 증가한다. | 2010.02.22 | 이종구*57 | 2010.02.22 | 7607 |
618 | ♥ 조기수축, Premature Contraction | 2010.03.03 | 이종구*57 | 2010.03.03 | 7828 |
617 | ♥ 새 약물방출스텐트는 금속스텐트에 비해 심근경색증/사망률을 증가 가능 | 2010.03.08 | 이종구*57 | 2010.03.08 | 6725 |
616 | ♥ 심방세동 | 2010.03.10 | 이종구*57 | 2010.03.10 | 7440 |
615 | 약물방출 스텐트(DES)를 사용시 심근경색증, 사망률, 재시술이 증가 | 2010.03.15 | 이종구*57 | 2010.03.15 | 7084 |
614 | ♥ 발작성 빈맥 | 2010.03.17 | 이종구*57 | 2010.03.17 | 7838 |
613 | ♥ 급성관상동맥증후군(ACS)에서 관상동맥확장술(PCI)의 역할 | 2010.03.22 | 이종구*57 | 2010.03.22 | 7330 |
612 | ♥ 소리 없는 살인자 고혈압 | 2010.03.24 | 이종구*57 | 2010.03.24 | 7378 |
611 | ♥ 만성관상동맥 폐쇄증에서 관상동맥확장술이 필요한가? | 2010.03.29 | 이종구*57 | 2010.03.29 | 7875 |
610 | ♥ 고혈압의 합병증 | 2010.03.31 | 이종구*57 | 2010.03.31 | 6917 |
609 | ♥ 관상동맥확장술(PCI)과 우회로수술(CABG)이후의 약물치료 | 2010.04.05 | 이종구*57 | 2010.04.05 | 8075 |
608 | ♥ 심장병과 당뇨병 | 2010.04.07 | 이종구*57 | 2010.04.07 | 7223 |
607 | ♥ 허혈성심장질환 환자에서 흔히 보는 베타차단제의 오해 | 2010.04.12 | 이종구*57 | 2010.04.12 | 7283 |
606 | ♥ 심근경색증 | 2010.04.14 | 이종구*57 | 2010.04.14 | 8998 |
605 | ♥ 혈관경련성 협심증(Vasospastic Angina)의 치료 | 2010.04.19 | 이종구*57 | 2010.04.19 | 12426 |
604 | 심근경색증 환자를 위한 조언 | 2010.04.21 | 이종구*57 | 2010.04.21 | 6909 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)